Drug Trial Radar · NCT06444815
A Study of VET3-TGI in Patients With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Sep 16, 2024
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- KaliVir ImmunotherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).
Conditions
- Solid Tumor, Adult
- Microsatellite Stable Colorectal Cancer
- Head and Neck Squamous Cell Carcinoma
- Cervical Cancer
- Kidney Cancer
- Renal Cell Carcinoma
- Melanoma Stage IV
- Merkel Cell Carcinoma of Skin
- Mesothelioma
- Non-small Cell Lung Cancer
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Urothelial Carcinoma Bladder
- Squamous Cell Carcinoma
Interventions
VET3-TGIDrug
Oncolytic vaccinia virus engineered with immunomodulatory transgenes
AtezolizumabDrug
anti-pd-L1 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events with VET3-TGI alone or in combination with atezolizumabTime frame: 108 months
- Incidence of dose limiting toxicities reported with VET3-TGI alone or in combination with atezolizumabTime frame: 4 weeks
- Determine the recommended Phase 2 doseTime frame: 4 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
USC/Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UC Irvine Health
Orange, California · Recruiting
University of Miami
Miami, Florida · Recruiting
Community Health Network
Indianapolis, Indiana · Active not recruiting
UPMC- Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Mary Crowley Cancer Research/Sarah Cannon Research Institute
Dallas, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Washington, Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.